Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXG +3.76%41 EV-to-EBITDA is 8.80 as of Aug. 20, 2026. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Interpace Biosciences ranks better than 73.5% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Interpace Biosciences's enterprise value is $43.41 Mil.
Interpace Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $4.93 Mil. Therefore, Interpace Biosciences's EV-to-EBITDA for today is 8.80.
The historical rank and industry rank for Interpace Biosciences's EV-to-EBITDA or its related term are showing as below:
IDXG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -347.87 Med: -0.88 Max: 25.04
Current: 8.8
During the past 13 years, the highest EV-to-EBITDA of Interpace Biosciences was 25.04. The lowest was -347.87. And the median was -0.88.
IDXG's EV-to-EBITDA is ranked better than 73.5% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 17.21
vs IDXG: 8.80
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Interpace Biosciences's PE Ratio (TTM) for today is calculated as:
Interpace Biosciences's share price for today is $1.629.
Interpace Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.890.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Interpace Biosciences EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Interpace Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's EV-to-EBITDA falls into.
Interpace Biosciences's current Enterprise Value is $43.41 Mil.
Interpace Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (IDXG) has a EV-to-EBITDA of 8.80 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Interpace Biosciences. According to the industry distribution chart, Interpace Biosciences ranks #31 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 26.5%.
Is Interpace Biosciences' EV-to-EBITDA too high?
Interpace Biosciences' current EV-to-EBITDA is 8.80. The Medical Diagnostics & Research industry median EV-to-EBITDA is 17.21. Interpace Biosciences' value of 8.80 is 48.9% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #31 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' EV-to-EBITDA compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #31 out of 117 companies for EV-to-EBITDA. This puts Interpace Biosciences in the upper half of its industry. The industry median EV-to-EBITDA is 17.21. Interpace Biosciences' value of 8.80 is 48.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 17.21, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current EV-to-EBITDA of 8.80 is 48.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Interpace Biosciences. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 17.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current EV-to-EBITDA is 8.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.63 — trading 714.5% above its estimated fair value. The current EV-to-EBITDA is 8.80 and 48.9% below the Medical Diagnostics & Research industry median of 17.21. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current EV-to-EBITDA is 8.80 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.63 is trading 714.5% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
EV-to-EBITDA: 8.80
GF Value™: $0.20 vs. price of $1.63 (714.5% above fair value)
Industry Position: 48.9% below the Medical Diagnostics & Research median (#31 of 117)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
